C12N 2760/20111
Lyssavirus
Official title: Lyssavirus, e.g. rabies virus
C12N2760/20111 (Lyssavirus) appears on 265 US grants and 291 published applications in this corpus.
Search patents in C12N- Granted patents
- 265
- Published applications
- 291
- Assignees
- 179
- Inventors
- 602
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 2 | 0 |
| 1978 | 3 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 4 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 7 | 0 |
| 1988 | 4 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 14 | 0 |
| 1999 | 6 | 0 |
| 2000 | 7 | 0 |
| 2001 | 7 | 2 |
| 2002 | 4 | 6 |
| 2003 | 5 | 11 |
| 2004 | 8 | 7 |
| 2005 | 1 | 8 |
| 2006 | 4 | 8 |
| 2007 | 6 | 5 |
| 2008 | 3 | 13 |
| 2009 | 3 | 6 |
| 2010 | 9 | 12 |
| 2011 | 4 | 12 |
| 2012 | 7 | 10 |
| 2013 | 6 | 12 |
| 2014 | 9 | 12 |
| 2015 | 13 | 12 |
| 2016 | 5 | 11 |
| 2017 | 11 | 17 |
| 2018 | 9 | 10 |
| 2019 | 13 | 15 |
| 2020 | 13 | 17 |
| 2021 | 8 | 15 |
| 2022 | 14 | 18 |
| 2023 | 11 | 19 |
| 2024 | 9 | 17 |
| 2025 | 5 | 10 |
| 2026 | 2 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/20134Use of virus or viral component as vaccineIndexing code162
- C12N 2760/20122New viral proteins or individual genes, new structural or functional aspects ofIndexing code119
- C12N 2760/20141Use of virus, viral particle or viral elements as a vectorIndexing code27
- C12N 2760/20151Methods of production or purification of viral materialIndexing code21
- C12N 2760/20171Demonstrated in vivo effectIndexing code19
- C12N 2760/20161Methods of inactivation or attenuationIndexing code14
- C12N 2760/20121Viruses as suchIndexing code4
- C12N 2760/20133Use of viral protein as therapeutic agent other than vaccineIndexing code4
Recent patents
- Drug delivery composition26 May 2026US 12,636,258 B2Japan Science and Technology Agency
- RNA construct10 Mar 2026US 12,569,548 B2Imperial College Innovations Limited
- Artificial nucleic acid molecules for improved protein expression14 Oct 2025US 12,442,005 B2CureVac AG
- Vaccine composition for preventing rabies, and preparation method thereof15 Jul 2025US 12,357,685 B2Bioapplications Inc.
- Methods of producing and characterizing virus vaccine and virus vaccine composition13 May 2025US 12,297,461 B2Guangzhou Realbenefitspot Pharmaceutical Co., Ltd.
- Expression construct10 Sep 2026US 2026/0265777 A1Lentitek Ltd
- Arrdc1-mediated microvesicle-based delivery of therapeutic agents to cells of the peripheral nervous system27 Aug 2026US 2026/0248957 A1Turn Biotechnologies, Inc.
- Sarna delivery system, preparation method therefor and use thereof23 Apr 2026US 2026/0110000 A1Zhejiang Free Trade Zone Hongan Base Biotechnology Co., Ltd.
- Lipid nanoparticle mrna vaccines2 Apr 2026US 2026/0090989 A1Acuitas Therapeutics, Inc.
- Compositions and methods for making and using stabilized enveloped viruses by spray-drying and lyophilization2 Apr 2026US 2026/0091106 A1The Regents of the University of Colorado, a body corporate
Most cited
By later US patents
- Recombinant infectious non-segmented negative strand RNA virus156US 6,033,886 A2000
- Recombinant avipox virus and immunological use thereof151US 5,174,993 AHealth Research, Inc. · 1992
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Recombinant poxvirus host range selection system127US 5,225,336 AHealth Research, Inc. · 1993